Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer

19 Oct 2020

Abstract excerpt

FMS-like tyrosine kinase 3 (FLT3) plays a key role in hematopoiesis. However, the oncogenic role of FLT3 amplification in patients with metastatic colorectal cancer (mCRC) remains unclear. Here, we aimed to evaluate the characteristics, prognosis, and treatment efficacy of an FLT3 inhibitor (regorafenib) in patients with mCRC with FLT3 amplifications. Tumor tissue samples from 2329 patients were sequenced using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Chronic Lymphocytic Leukemia Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33075166
DOI: 10.1111/cas.14693

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancerPMID 33075166Read ↗

Response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600E MT colon cancer patients with acquired C-MET amplification and TPM4- ALK fusion: case report and review of literatureSemantic proximity Read ↗

[Clinical Characteristics and Prognostic Relevance of Co-Mutated Genes in Acute Myeloid Leukemia Patients with FLT3 Mutations].Semantic proximity Read ↗

Normal and oncogenic FLT3.Semantic proximity Read ↗

Molecular insight of regorafenib treatment for colorectal cancer.Semantic proximity Read ↗

Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer PatientsSemantic proximity Read ↗

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.Semantic proximity Read ↗

Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancerSemantic proximity Read ↗

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity Read ↗

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Semantic proximity Read ↗

Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib.Semantic proximity Read ↗

The role of FLT3 in haematopoietic malignancies.Semantic proximity Read ↗

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.